Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.
Saved in:
| Title: | Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma. |
|---|---|
| Authors: | Cheng CL; Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan., Huang TC; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tuan YH; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Liang JF; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan., Wang SM; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan., Chen LC; Roche Product Ltd, Taipei, Taiwan., Wu YC; Roche Product Ltd, Taipei, Taiwan., Chang CH; Clinical Trial Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2025 Dec 04; Vol. 17, pp. 17588359251396884. Date of Electronic Publication: 2025 Dec 04 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359251396884 |
